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ABSTRACT: 
Leukopenia in kidney transplant patients is frequent, it causes potentially life-threatening complications, 
but it is often poorly characterized. Opportunistic infections, immunologic disturbances and drug-related 
toxicity are principal causes of single or multilineage cytopenias. Tacrolimus-induced leukopenia is a less 
recognized but frequent complication.
We describe one patient with leukopenia developing within seven months after renal transplant. After 
excluding other potential causes, tacrolimus was switched to cyclosporine, with recovery of white blood 
cell count.
Based on the clinical report, the authors reviewed causes of post-transplant leukopenia, focusing on the 
diagnostic investigation. Early diagnosis and interventions are fundamental to improve prognosis.
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RESUMO 
A leucopenia no doente transplantado renal é comum, causa complicações com potencial risco de vida, 
mas é muitas vezes mal caracterizada. As infecções por agentes oportunistas, distúrbios imunológicos e 
toxicidade secundária a fármacos são as principais causas de citopenias de uma ou várias linhas. A leu-
copenia induzida pelo tacrolimus é uma complicação frequente, mas pouco reconhecida.
Descrevemos um doente com início de leucopenia sete meses pós-transplante renal. Após excluir outras 
potenciais causas, o tacrolimus foi substituído pela ciclosporina, com recuperação da contagem leucocitária.
Baseado no caso clínico, os autores fizeram uma revisão das causas de leucopenia pós-transplante e 
sua investigação. O diagnóstico e tratamento precoces são fundamentais na melhoria do prognóstico.
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INTRODUCTION 
Leukopenia refers to a low total white blood cell 
count and may be due either to lymphopenia and/
or neutropenia. Most publications use leukopenia 
and neutropenia interchangeably, which may be a 
source of confusion1. Leukopenia is defined as leu-
kocyte count inferior to 4.000/μL and neutropenia is 
defined as, at least, a neutrophil value <2000/μL1.
The estimated incidence of leukopenia in kidney 
transplant recipients ranges from 10% to 55.5%, 
while neutropenia has been reported in between 
4.9% and 37.5% of patients2.
There are several factors that contribute to leu-
kopenia after kidney transplantation. The most preva-
lent are drug toxicity, systemic infection and post-
transplant lymphoproliferative disease1. In previous 
reports, the incidence of neutropenia in the first year 
post-transplant was significantly associated with 
mycophenolate mofetil (MMF)-tacrolimus (TAC) com-
bination therapy3.
Tacrolimus is a cornerstone therapy in preventing 
rejection in renal transplantation but has several side 
effects, such as new-onset post-transplant diabetes 
(8.4-9.8%)4, hypertension (13-62%), hyperlipidemia 
(23%), neurotoxicity (7-32%)5, electrolytic distur-
bances and nephrotoxicity6.
Leukopenia related to the use of TAC is described 
in 13-48% of cases. Besides this high frequency, 
there are only few case-reports in the literature focus-
ing the role of TAC as the culprit agent in 
leukopenia3.
We report a case of post-transplant leukopenia 
in a renal transplant recipient under tacrolimus ther-
apy, where tacrolimus seems to be the offending 
agent.
CASE REPORT 
A 56-year-old man with end-stage renal failure due 
to IgA nephropathy underwent living donor renal 
transplantation, in May 2011. Initial immunosuppres-
sive therapy was basiliximab, prednisolone, MMF and 
TAC. Both donor and recipient were CMV positive 
and no valganciclovir was used. There were no surgi-
cal or infectious complications, delayed graft function, 
neither acute rejection episodes. Peripheral blood 
count was normal and renal function remained stable 
at levels of plasmatic creatinine (Cr) of 1.2-1.4 mg/
dL, for the first post-transplantation months. Main-
tenance therapy consisted in prednisolone, MMF, TAC, 
trimethoprim-sulphamethoxazol and ranitidine.
Seven months later, leukopenia (3760/μL) and 
neutropenia (1750/μL) were documented. Haemoglo-
bin and platelet counts were normal and renal func-
tion remained stable (Cr: 1,23mg/dL).
Bacterial, fungal and viral infections [including 
herpes simplex virus (HSV), cytomegalovirus (CMV), 
Epstein-Barr virus (EBV), parvovirus B19 (PV B19), 
hepatitis virus and human immunodeficiency virus] 
were excluded. Peripheral blood immunophenotyping 
analysis revealed no abnormalities, particularly dys-
plastic changes or monoclonal proliferation, and bone 
marrow examination was normal.
Trimethoprim-sulphamethoxazol, MMF and raniti-
dine were discontinued as soon as leukopenia was 
confirmed, without improvement of leukocyte count.
Ten months after transplantation, leukopenia 
(2500/uL) and neutropenia (670/uL) progressively 
worsened and TAC was replaced by cyclosporine 
(CsA). After calcineurin-inhibitor conversion, white 
blood cell (WBC) count normalized. The patient 
remained asymptomatic with normal peripheral blood 
count. Two months later, MMF was reintroduced with 
persistence of normal WBC count.
DISCUSSION 
Haematologic abnormalities are common in renal 
transplanted patients and can cause potentially life-
threatening complications. Opportunistic (especially 
viral) infections, immunologic disturbances [such as 
haemophagocytic syndrome (HPS), graft versus host 
disease (GVHD), post-transplant lymphoproliferative 
disease (PTLD)] and drug-related toxicity are the 
main causes of single or multilineage cytopenias1,7. 
Cytomegalovirus, PV B19, EBV and HSV are common 
causes of infection-induced cytopenias in renal trans-
plant recipients1,7.
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Cytomegalovirus is the most commonly recognized 
opportunistic pathogen, occurring in 20 to 60% of 
transplant recipients8. Cytomegalovirus seronegative 
recipients of seropositive grafts have the highest 
risk of recurrent, invasive and ganciclovir-resistant 
CMV infection8. Fever, constitutional symptoms, 
hepatitis, encephalitis, pneumonia and gastrointes-
tinal bleeding are typical of CMV infection9. Leuko-
penia is present in as many as 20% of patients with 
active infection9. This virus causes myelosuppression 
by either directly infecting hematopoietic progenitor 
cells or stromal elements, interfering with the sup-
portive microenvironment. Moreover, drugs used in 
prophylaxis, like valganciclovir, and treatment of CMV 
infection frequently cause leukopenia10.
Parvovirus B19, which target specificity for human 
erythroid-lineage cells, infects the majority of humans 
and typically inhibits erytropoiesis7. Anaemia was 
the predominant laboratory abnormality (98.8%), but 
leukopenia (37.5 %) and thrombocytopenia (21%) 
were also reported by Albert et al. in their review 
of 91 transplanted patients (54% renal transplant 
patients) with PV B19 infection11. Bone marrow biopsy 
showing pathognomonic findings of giant pro-eryth-
roblasts with prominent intranuclear inclusions con-
firm the diagnosis. Treatment consists in immunosup-
pressive dose reduction, red blood cell transfusion 
and, in the absence of clinical response, high-dose 
immunoglobulin11.
Epstein Barr Virus (EBV) is a known causative agent 
of infectious mononucleosis, a usually benign disorder 
more prevalent in adolescents and young adults. The 
virus remains latent in B lymphocytes after primary 
infection12. Acute or recurrent infection may cause 
fever, organomegaly, lymphadenopathy and leukope-
nia. Treatment is based on immunosuppression reduc-
tion, ganciclovir and immunoglobulin12.
Herpes simplex virus has a seroprevalence of 60% 
in the general population and an estimated incidence 
of 53% in renal transplant recipients12. Reactivation 
after transplantation is frequent but clinical disease 
is rare. Leukopenia is the most common haematologic 
manifestation of HSV infection, but other lines can 
be involved7. Oral or genital mucocutaneous lesions 
are typical of HSV infection. Other more serious sys-
temic manifestations, such as HSV encephalitis are 
extremely rare, since introduction of acyclovir in the 
prophylaxis and treatment of HSV infection.
Our patient did not have fever, constitutional 
symptoms, organomegaly, lymphadenopathy or 
mucocutaneous lesions; microbiological examination 
was negative for CMV, PV B19, EBV, HSV acute infec-
tion, and bone marrow biopsy was normal. Oppor-
tunistic infections were excluded as potential causes 
for patient’s leukopenia.
Acquired haemophagocytic syndrome (HPS) is a 
rare, aberrant immune response in reaction to a 
precipitating cause, such as opportunistic infections. 
It is a life-threatening systemic inflammatory disease 
in which there is haemophagocytosis by non-neo-
plastic macrophages in the bone marrow, liver, lymph 
nodes and spleen13. Karras et al. reported an inci-
dence of 0.4% among RT patients with an average 
time of 52 days after transplant13. The clinical features 
include fever, hepatosplenomegaly, lymphadenopa-
thy, skin rash, jaundice, dyspnoea, cachexia, and 
neurological dysfunction. The laboratory findings 
include pancytopenia, abnormal liver tests, elevated 
LDH and hypertriglyceridemia14. Bone marrow biopsy 
showing haemophagocytosis confirms the diagnosis. 
No specific therapy is recommended other than treat-
ment of the precipitating cause and supportive care. 
The mortality rate is as high as 50%14.
Graft versus host disease (GVHD) is caused by 
proliferation of allograft-associated lymphocytes in 
the immunosuppressed recipient, with subsequent 
immune-mediated attack by donor cells against host 
tissues. Usually, it occurs most frequently following 
small bowel and liver transplant, followed by lung 
and kidney transplantation. Graft versus host disease 
typically occurs with a median onset of 77 days after 
kidney transplant7 and clinical presentation includes 
fever, rash, diarrhoea and pancytopenia15. Diagnosis 
is achieved by the demonstration of histological fea-
tures of GVHD and confirmation of lymphocyte mac-
rochimerism in the peripheral blood, marrow and 
affected tissues. In most reports, patients were 
treated by increasing immunosuppression and hae-
matopoietic cytokines to support bone marrow func-
tion15. Prognosis is poor with reported mortality rates 
of 100% in lung, 75% in liver and 30% in other solid 
organ-transplant recipients7.
As previously described EBV remains latent in B 
lymphocytes after primary infection. In the post-
transplant period, immunosuppression provides 
expansion of B lymphocytes with increased risk of 
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post-transplant lymphoproliferative disorders12. Com-
pared with other transplant populations, renal trans-
plant recipients have the lowest risk of acquiring 
PTLD (1-3%), as they require lower dose of immu-
nosuppression7. Post-transplant lymphoproliferative 
disease most commonly occurs in the first year post 
transplant and presents with fever, lymphadenopathy 
and haematologic manifestations. First-line treatment 
consists in the reduction or suspension of immuno-
suppressive therapy. Other therapeutic regimens, 
such as ganciclovir and interferon-alfa have shown 
no consistent results16.
Immunologic disturbances were excluded in our 
patient because he was asymptomatic, with normal 
blood immunophenotyping and bone marrow histol-
ogy. Bone marrow biopsy also excluded infiltrative 
diseases as other causes of leukopenia. Bone mar-
row aplasia and thrombotic microangiopathy (TMA) 
were less likely as the erythroid and megakaryocytic 
lineages have not been affected.
The diagnosis of drug-related cytopenias is difficult 
because there are no guidelines on management or 
specific tests to identify the culprit agent. If drug-
related neutropenia is suspected, the diagnostic 
strategy involves discontinuing the most likely agent. 
This approach is not risk free, as it may trigger a 
rejection or an opportunistic infection.
MMF18 and valganciclovir10 are the most frequently 
drugs involved in leukopenia in renal transplant 
recipients. Antithymocyte globulin (ATG), rituximab, 
sirolimus, azathioprine and tacrolimus related leu-
kopenia have been described3,18. Other non-immu-
nossupessive drugs, such as trimethoprim/sulfame-
thoxazole, clopidogrel and ticlopidine are also 
relevant causes of pancytopenia in RT patients19.
Mycophenolate mofetil-induced leukopenia was 
reported in 13-35% of patients17. The marrow effects 
of MMF are dose dependent and correlate with trough 
levels of the active metabolite, the mycophenolic 
acid. During lymphocyte proliferation, MMF reversibly 
and non-competitively inhibits the inosine mono-
phosphate dehydrogenase, a rate-limiting enzyme 
for de novo purine synthesis and causes lymphope-
nia. The MMF effect is relatively selective to prolif-
erating lymphocytes, but it is also associated with 
other reversible cytopenias, such as leukopenia and 
anaemia7.
Co-administered agents with myelosuppressive 
effects, especially valganciclovir, increase the risk of 
leukopenia10. Leukopenia, usually reversible, is the 
most frequent side-effect of valganciclovir and is 
reported in 10-13% of cases10. Ganciclovir and val-
ganciclovir can also lead to multilineage cytopenias 
or severe drug-related pancytopenia7. Kennedy et al 
suggest that the interaction of ganciclovir with MMF 
potentiates dysgranulopoiesis, contributing to 
leukopenia20.
Sirolimus is an m-TOR inhibitor and causes leu-
kopenia, anaemia and thrombocytopenia. Generally, 
these haematologic changes are dose-dependent and 
not clinically relevant. It seems that there is a direct 
anti-proliferative effect on bone marrow that explains 
leukopenia related to this drug21.
Azathioprine-induced leukopenia is described in 
more than 50% of RT patients. After administration, 
azathioprine is rapidly converted to 6-mercaptopu-
rine, which undergoes extensive metabolism and the 
end-products are excreted via urine18. Allopurinol 
inhibits the enzyme xantine-oxidase, a degradating 
enzyme of 6-mercaptopurine and increases azathio-
prine levels. Aditionally, renal dysfunction causes 
azathioprine end-products accumulation, with a 
higher risk of leukopenia22.
Trimethoprim/sulfamethoxazole-associated cytope-
nias may be due to induction of folate deficiency, 
haemolysis in patients with unrecognized glucose-
6-phosphate dehydrogenase deficiency or drug-
induced haemolytic anaemia7.
In our case, MMF, trimethoprim/sulfamethoxazole 
and ranitidine interruption did not lead to resolution 
of leukopenia and TAC-induced leukopenia was 
suspected.
Leukopenia exclusively linked with TAC is a com-
mon complication, described in 13-48% of cases, 
but it is rarely considered. The pathophysiologic 
mechanism has not been completely clarified and 
four mechanisms were proposed3. The best known 
mechanism involves pharmacokinetic interaction 
between TAC and MMF: TAC inhibits MMF glucoro-
nidation and increases its bioavailability. Mycophe-
nolate mofetil inhibits the rate-limiting enzyme of 
de novo purine synthesis during lymphocyte pro-
liferation, causing leukopenia7. This may justify why, 
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in the Symphony trial, leukopenia was significantly 
more frequent with TAC-MMF than with CsA and 
MMF or sirolimus with MMF associations (13.4% vs. 
10.2% vs. 10.3%, respectively)5.
When immunosuppressive protocols include MMF-
TAC and leukopenia develops, the reduction of the 
MMF dose is the rule and determination of myco-
phenolic acid levels may be indicated.
However, in our patient, leukopenia persisted after 
discontinuing MMF. A second mechanism3 proposed 
that leukopenia is due to direct inhibition of myeloid 
cells by TAC, with a maturation arrest in myeloid 
precursor cells. Another hypothesis speculates the 
effect of TAC on mononuclear accessory cells, with 
production of cytokines causing greater death of 
neutrophils3. The last mechanism postulates the for-
mation of autoantibodies against myeloid precursors 
of mature neutrophils, but such antibodies were not 
identified3.
Independently of the pathophysiologic mechanism, 
in our case, conversion of TAC to CsA allowed the 
resolution of leukopenia and the reintroduction of 
MMF, with no use of granulocyte colony stimulating 
factor (G-CSF). There are no guidelines on the use 
of G-CSF for the treatment of leukopenia after RT, 
and G-CSF is associated with a reduction in time of 
agranulocytosis, antibiotic use and length of hospital 
stay, without side-effects, such as acute rejection23. 
Some authors suggest using C-GSF to allow mainte-
nance of MMF in low dose, reducing the risk of acute 
rejection1. However, its use is not associated with 
reduction of mortality and definitive treatment of 
leukopenia requires a reduction or suspension of 
the culprit drug23.
In a time where transplant programmes are increas-
ing, our case may alert physicians to the need of 
systematic evaluation of cytopenias after transplanta-
tion. Attention to the time of onset must be paid 
because GVHD, HPS, and TMA are more likely to 
occur in the first few months and PTLD is most com-
mon in the first year after transplant. Drug-related 
cytopenia(s) should be considered and opportunistic 
infections should always be investigated as a poten-
tial precipitating cause of cytopenia(s), either as the 
direct agent of marrow suppression or as the trigger 
for HPS or immune cytopenia(s). Early investigation 
of pancytopenia by diagnostic bone marrow biopsy 
is warranted, because it is often the presenting symp-
tom of life-threatening pathologies, such as GVHD, 
PTLD or unsuspected opportunistic infections, condi-
tions that may have a better prognosis if early inter-
ventions are undertaken.
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